Clinical trials have demonstrated that tirzepatide can reduce HbA1c by up to 2.5% (at the highest doses) and body weight by approximately 1520% in people without diabetes (SURMOUNT trials) and somewhat less in those with type 2 diabetes (SURPASS trials), when combined with lifestyle modifications
The research is preclinical and ongoing, which is why BPC-157 is prescribed off-label
Medical Writing/Editorial Assistance Medical writing support was provided by Carrie Fidler and Alice Bedwell of HEOR Ltd
Per ADA 2026 Standards of Care, treatment is individualized based on A1C targets, comorbidities (CVD, CKD, heart failure), hypoglycemia risk, weight effects, cost, and patient preference
10.1161/JAHA.115.002767 136 SeshadriS.BeiserA.SelhubJ.JacquesP
The important consideration isn't just monthly cost but the total value equation: what's included in that monthly price, what level of clinical support comes with it, which pharmacies are compounding the medications, and what happens if you have questions or need dosage adjustments between scheduled check-ins
.jpg?sfvrsn=f85d055_0)
